Jw Pharmac Net Assets
Jw Pharmac net assets. Based on the latest financial reports, Jw Pharmac (001060) has net assets worth ₩381.78 Billion KRW (≈ $258.73 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩621.61 Billion ≈ $421.25 Million USD) and total liabilities (₩239.83 Billion ≈ $162.53 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Jw Pharmac (001060) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩381.78 Billion |
| % of Total Assets | 61.42% |
| Annual Growth Rate | 6.03% |
| 5-Year Change | 95.91% |
| 10-Year Change | 33.68% |
| Growth Volatility | 13.65 |
Net Assets of Jw Pharmac (2000–2025)
Net assets of Jw Pharmac from 2000 to 2025. This chart illustrates how Jw Pharmac's net assets have evolved over time, based on quarterly financial data. See 001060 equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Jw Pharmac (2000–2025)
The table below shows the annual net assets of Jw Pharmac from 2000 to 2025. For live market cap and overall valuation, see Jw Pharmac market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩369.37 Billion ≈ $250.32 Million |
+12.10% |
| 2024-12-31 | ₩329.49 Billion ≈ $223.29 Million |
+24.13% |
| 2023-12-31 | ₩265.44 Billion ≈ $179.89 Million |
+17.58% |
| 2022-12-31 | ₩225.76 Billion ≈ $152.99 Million |
+19.74% |
| 2021-12-31 | ₩188.54 Billion ≈ $127.77 Million |
-9.12% |
| 2020-12-31 | ₩207.47 Billion ≈ $140.60 Million |
-9.83% |
| 2019-12-31 | ₩230.09 Billion ≈ $155.93 Million |
-11.54% |
| 2018-12-31 | ₩260.11 Billion ≈ $176.27 Million |
-3.94% |
| 2017-12-31 | ₩270.78 Billion ≈ $183.50 Million |
-2.00% |
| 2016-12-31 | ₩276.31 Billion ≈ $187.25 Million |
+22.58% |
| 2015-12-31 | ₩225.41 Billion ≈ $152.75 Million |
+0.71% |
| 2014-12-31 | ₩223.83 Billion ≈ $151.68 Million |
+11.50% |
| 2013-12-31 | ₩200.74 Billion ≈ $136.04 Million |
+22.65% |
| 2012-12-31 | ₩163.66 Billion ≈ $110.91 Million |
-3.87% |
| 2011-12-31 | ₩170.25 Billion ≈ $115.38 Million |
-1.29% |
| 2006-12-31 | ₩172.48 Billion ≈ $116.89 Million |
+44.40% |
| 2005-12-31 | ₩119.44 Billion ≈ $80.95 Million |
+0.04% |
| 2004-12-31 | ₩119.39 Billion ≈ $80.91 Million |
+6.04% |
| 2003-12-31 | ₩112.60 Billion ≈ $76.31 Million |
+11.79% |
| 2002-12-31 | ₩100.72 Billion ≈ $68.26 Million |
+13.27% |
| 2001-12-31 | ₩88.92 Billion ≈ $60.26 Million |
+4.03% |
| 2000-12-31 | ₩85.47 Billion ≈ $57.93 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jw Pharmac's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 24445.8% over the analyzed period, indicating profitable operations and earnings retention.
Jw Pharmac Net Assets Breakdown (December 2025)
Jw Pharmac net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩214.57 Billion | 58.09% |
| Other Components | ₩154.80 Billion | 41.91% |
| Total Equity | ₩369.37 Billion | 100.00% |
Jw Pharmac Competitors by Market Cap
The table below lists competitors of Jw Pharmac ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhenhai PetroChem Engineering
SHG:603637
|
$349.97 Million |
|
Jiayuan Science and Technology Co.Ltd.
SHE:301117
|
$350.09 Million |
|
Haleon PLC
LSE:HLN
|
$350.22 Million |
|
WhiteFiber, Inc. Ordinary Shares
NASDAQ:WYFI
|
$350.26 Million |
|
Tidewater Midstream and Infrastructure Ltd
TO:TWM
|
$349.94 Million |
|
Komipharm International Co. Ltd
KQ:041960
|
$349.86 Million |
|
Roma Green Finance Limited Ordinary Shares
NASDAQ:ROMA
|
$349.85 Million |
|
Wuhan Ligong Guangke Co Ltd
SHE:300557
|
$349.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jw Pharmac's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 329,486,740,930 to 369,369,598,680, a change of 39,882,857,750 (12.1%).
- Net income of 61,511,192,810 contributed positively to equity growth.
- Dividend payments of 11,068,208,750 reduced retained earnings.
- Share repurchases of 9,539,885,050 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩61.51 Billion | +16.65% |
| Dividends Paid | ₩11.07 Billion | -3.0% |
| Share Repurchases | ₩9.54 Billion | -2.58% |
| Other Changes | ₩-1.02 Billion | -0.28% |
| Total Change | ₩- | 12.10% |
Book Value vs Market Value Analysis
This analysis compares Jw Pharmac's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.75x to 1.40x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩13077.48 | ₩22900.00 | x |
| 2018-12-31 | ₩12533.97 | ₩22900.00 | x |
| 2019-12-31 | ₩11131.31 | ₩22900.00 | x |
| 2020-12-31 | ₩10041.95 | ₩22900.00 | x |
| 2021-12-31 | ₩9182.78 | ₩22900.00 | x |
| 2022-12-31 | ₩10656.13 | ₩22900.00 | x |
| 2023-12-31 | ₩11440.15 | ₩22900.00 | x |
| 2024-12-31 | ₩14205.66 | ₩22900.00 | x |
| 2025-12-31 | ₩16380.38 | ₩22900.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jw Pharmac utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.65%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.93%
- • Asset Turnover: 1.28x
- • Equity Multiplier: 1.64x
- Recent ROE (16.65%) is above the historical average (5.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 8.63% | 2.67% | 0.69x | 4.65x | ₩-1.17 Billion |
| 2001 | 11.54% | 3.44% | 0.77x | 4.33x | ₩1.37 Billion |
| 2002 | 10.81% | 3.08% | 0.92x | 3.83x | ₩818.22 Million |
| 2003 | 9.51% | 2.86% | 0.91x | 3.66x | ₩-552.28 Million |
| 2004 | 10.58% | 3.19% | 0.86x | 3.84x | ₩685.34 Million |
| 2005 | 7.60% | 2.26% | 0.84x | 4.00x | ₩-2.87 Billion |
| 2006 | 7.29% | 2.65% | 0.85x | 3.23x | ₩-4.34 Billion |
| 2013 | 1.12% | 0.57% | 0.67x | 2.94x | ₩-17.83 Billion |
| 2014 | 0.28% | 0.15% | 0.69x | 2.65x | ₩-21.77 Billion |
| 2015 | 0.87% | 0.45% | 0.71x | 2.73x | ₩-20.52 Billion |
| 2016 | -3.96% | -2.34% | 0.72x | 2.36x | ₩-38.56 Billion |
| 2017 | -0.27% | -0.15% | 0.80x | 2.33x | ₩-27.82 Billion |
| 2018 | 3.10% | 1.50% | 0.90x | 2.28x | ₩-17.95 Billion |
| 2019 | -10.99% | -4.94% | 0.89x | 2.49x | ₩-48.28 Billion |
| 2020 | -7.35% | -2.78% | 1.00x | 2.65x | ₩-35.99 Billion |
| 2021 | -0.48% | -0.16% | 0.96x | 3.15x | ₩-21.09 Billion |
| 2022 | 13.27% | 4.66% | 1.09x | 2.61x | ₩7.86 Billion |
| 2023 | 13.94% | 4.94% | 1.16x | 2.43x | ₩10.46 Billion |
| 2024 | 19.74% | 9.04% | 1.19x | 1.83x | ₩32.09 Billion |
| 2025 | 16.65% | 7.93% | 1.28x | 1.64x | ₩24.57 Billion |
Industry Comparison
This section compares Jw Pharmac's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $515,312,490,046
- Average return on equity (ROE) among peers: 4.51%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jw Pharmac (001060) | ₩381.78 Billion | 8.63% | 0.63x | $349.95 Million |
| Dongwha Pharm.Co.Ltd (000020) | $360.13 Billion | 4.96% | 0.24x | $98.24 Million |
| Yuhan Corp. (000100) | $862.60 Billion | 14.22% | 0.20x | $3.80 Billion |
| Yuhan Corp Preferred (000105) | $1.94 Trillion | 5.30% | 0.27x | $45.29 Million |
| Yuyu Pharma (000220) | $78.29 Billion | 7.52% | 0.42x | $40.47 Million |
| Yuyu Pharma Inc (000225) | $140.54 Billion | 5.80% | 0.47x | $13.42 Million |
| Yuyu Pharma Inc (000227) | $117.04 Billion | 1.10% | 0.32x | $32.52 Million |
| Ildong Holdings Co Ltd (000230) | $172.99 Billion | 13.36% | 0.64x | $44.50 Million |
| Samil Pharm (000520) | $56.08 Billion | -15.27% | 1.64x | $107.04 Million |
| Donga Socio Holdings (000640) | $914.25 Billion | 3.56% | 0.60x | $380.90 Million |
About Jw Pharmac
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more